We found that 5-aminolevulinic acid (5-ALA) and intraoperative MRI (iMRI) offer similar surgical outcomes in glioblastoma resection, with no superiority of iMRI

In a post by Sotirios Bisdas on Linkedin, it says, “I am thrilled to share our team’s recent study in neuro-oncology, published in the prestigious Journal of Clinical Oncology, that provides some significant insights.

–> We found that 5-aminolevulinic acid (5-ALA) and intraoperative MRI (iMRI) offer similar surgical outcomes in glioblastoma resection, with no superiority of iMRI. Importantly, 5-ALA could be an economically viable alternative given the high acquisition and operational costs of iMRI.
–> Key findings indicate any residual tumor tissue adversely impacts overall survival (OS) and progression-free survival (PFS). Thus, a safe, complete resection is crucial, especially for patients with an unmethylated MGMT promoter.

I am incredibly proud of our devoted and brilliant team. Their tireless efforts in pursuing the highest standards of care and their commitment to improving patient outcomes are unparalleled.
Our findings emphasize the importance of precision, efficiency, and cost-effectiveness in neurosurgery, which could guide future practice.
Our work reaffirms the value of relentless scientific inquiry in our pursuit to battle glioblastoma.”

Journal of Clinical Oncology – Click here

Source: Sotirios Bisdas/Linkedin